ADC Therapeutics To Move Antibody Drug Conjugate ADCT-401 For Prostate Cancer Into Human Clinical Trials With Partner MedImmune
Published: May 19, 2014
LAUSANNE, Switzerland & LONDON--(BUSINESS WIRE)--ADC Therapeutics (ADCT), an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced today that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
Help employers find you! Check out all the jobs and post your resume.